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Abstract
Aims/hypothesis The Pune Children’s Study aimed to test
whether glucose and insulin measurements in childhood pre-
dict cardiovascular risk factors in young adulthood.
Methods We followed up 357 participants (75% follow-up) at
21 years of age who had undergone detailed measurements at
8 years of age (glucose, insulin, HOMA-IR and other indices).
Oral glucose tolerance, anthropometry, plasma lipids, BP, ca-
rotid intima–media thickness (IMT) and arterial pulse wave
velocity (PWV) were measured at 21 years.
Results Higher fasting glucose, insulin and HOMA-IR at
8 years predicted higher glucose, insulin, HOMA-IR, BP,
lipids and IMT at 21 years. A 1 SD change in 8 year variables
was associated with a 0.10–0.27 SD change at 21 years inde-
pendently of obesity/adiposity at 8 years of age. A greater rise
in glucose–insulin variables between 8 and 21 years was asso-
ciated with higher cardiovascular risk factors, including PWV.
Participants whose HOMA-IR measurement remained in the
highest quartile (n=31) had a more adverse cardiovascular risk
profile compared with those whose HOMA-IR measurement
remained in the lowest quartile (n=28).
Conclusions/interpretation Prepubertal glucose–insulin me-
tabolism is associated with adult cardiovascular risk and
markers of atherosclerosis. Our results support interventions
to improve glucose–insulin metabolism in childhood to re-
duce cardiovascular risk in later life.
Keywords Cardiovascular risk . Childhood insulin
resistance . Diabetes . Indians . Young adults
Abbreviations
CVD Cardiovascular disease
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
IMT Intima–media thickness
PWV Pulse wave velocity
ROC Receiver operating characteristic
Introduction
Since the demonstration of an association between birth size
and risk of type 2 diabetes and cardiovascular disease (CVD)
by Hales et al [1], a number of birth cohorts have been
established to document the life course evolution of chronic
non-communicable diseases [2–5]. Some of these cohorts
showed an inverse association between birthweight and child-
hood risk factors for type 2 diabetes and CVD [6, 7]. Few of
these prospective birth cohorts have reported follow-ups ex-
tending into adult life.
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It is recognised that a small elevation in plasma glucose
concentration in adults (lower than that defining diabetes) is
associated with an increased risk of later CVD [8–10]. This
has led to the creation of a ‘borderline’ group of ‘prediabetes’
and the concept of ‘dysglycaemia’ [11–13]. It is generally
believed that the increased CVD risk in such a situation is
related to ‘insulin resistance’, although some believe that
‘hyperinsulinaemia’ itself is responsible [14–18]. A number
of studies have demonstrated tracking of CVD risk factors
from childhood through to adulthood [19–22]. However, there
are very few studies which can relate childhood glucose and
insulin measurements to future risk of CVD. The Bogalusa
Heart Study showed childhood glucose and insulin concentra-
tions to be predictive of adult diabetes and CVD risk factors
[23, 24]. However, the ‘childhood’ measurements spanned
across puberty and extended into early adulthood (4–18 years
in one study and 5–23 years in the other), follow-up rates were
low, and the ‘adult’ measurements were spread over a wide
age range (19–39 years). Demonstration of an association be-
tween prepubertal insulin resistance and adult CVD risk will
allow us to highlight the importance of this phase in the life
course evolution of CVD risk.
India has high rates of diabetes [25] and in comparisonwith
Western populations Indians develop diabetes at a younger
age and lower BMI. A national survey in India demonstrated
a prevalence of 2.4% diabetes and 11.5% impaired glucose
tolerance in young people aged 20–29 years, and rates of
gestational diabetes in young women are high at ∼15% [26,
27]. Indians as a group are one of the most insulin-resistant
populations in the world [28] and it is thought that this con-
tributes to their high risk of diabetes and CVD. There is little
life course data to support this assumption.
The Pune Children’s Study was established in 1991 to ex-
amine the associations between birthweight and risk factors
for diabetes and CVD in later life. At 4 and 8 years of age, we
found an inverse association between birthweight and glu-
cose, insulin and HOMA-IR [2, 6].We have followed up these
children at 21 years of age and now examine the possibility
that insulin resistance in childhood will be associated with
future CVD risk.
Methods
The Pune Children’s Study has been described previously [2,
6]. Children born in the King Edward Memorial Hospital,
Pune, India, between 1987 and 1989 were studied during
childhood and again at the age of 21 years (Fig. 1). Ethics
permission for the study was obtained from the King
Edward Memorial Hospital Ethics Committee and informed
written consent was obtained from all participants.
The procedures used at 8 and 21 years were similar. The
participants were admitted to the Diabetes Unit, King Edward
Memorial Hospital, the evening before the investigations and
fasted overnight after a standard dinner. Anthropometry was
measured according to standardised protocols [6]. All children
were examined at 8 years by a paediatrician for pubertal as-
sessment. Acanthosis nigricans was examined in the neck and
201 participants studied at 4 years
190 participants studied at 4 years and 8 years
287 newly enrolled 8-year-old participants
477 participants studied at 8 years
6 died (1 kidney failure, 1 jaundice, 1 infection, 
1 trauma, 2 unknown)
17 declined to participate
94 untraceable
Total 360 participants studied at 21 years
357 participants studied at 8 and 21 years
3 missing 8 year data
Fig. 1 Flow diagram showing
enrolment and follow-up in the
Pune Children’s Study
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axillary regions by a trained observer and graded [29]. Grades
0 and 1 were rated as absence of acanthosis and grades ≥2
were rated as presence of acanthosis; the grade was used as a
dichotomous variable in the statistical analysis. BP was mea-
sured in the supine position after 15 min of rest, using an
oscillometric method (Dinamap; Critikon, Tampa, FL, USA
[at 8 years]; UA-767PC; A & D Instruments, Abingdon, UK
[at 21 years]). The average of two readings 5 min apart was
used. At 21 years, intima–media thickness (IMT, a surrogate
for atherosclerosis) was measured by one observer (ASK)
using ProSound Alpha 7 (Aloka, Tokyo, Japan) (linear array
probe 5–13 MHz) at the bifurcation of the common carotid
arteries [30]. IMT measurements were carried out on longitu-
dinal sections in the common carotid segment 1 cm proximal
to the bifurcation. A section showing maximum IMT on the
posterior wall was considered for documentation and the
average of three readings was taken. The observer also
examined for the presence of plaques. Intra-observer CV
was <3%. We measured pulse wave velocity (PWV) in
the brachial arteries using a non-invasive Windows-based
oscillometric technique (PeriScope; Genesis Medical
Systems, Chennai, India). This instrument has been val-
idated for PWV measurements [31]. PWV is a measure
of arterial compliance and is increased in stiffer arteries.
Intra- and inter-observer CVs were <2% and <10%, re-
spectively. The average of the measurements from right
and left was used for analysis of IMT and PWV.
The next morning, fasting venous blood samples were tak-
en for measurement of plasma glucose, insulin and lipids. An
OGTTwas carried out according to the WHO protocol, using
a dose of 1.75 g anhydrous glucose per kg body weight at
8 years and 75 g at 21 years. Blood samples were collected
for measurement of glucose and insulin at 30 and 120 min.
Laboratory analyses
Plasma glucose, cholesterol, HDL-cholesterol and triacylglyc-
erol concentrations were measured using standard enzymatic
methods (Spectrum; Abbott, Irving, TX, USA [at 8 years];
Hitachi 902; Roche Diagnostics, Mannheim, Germany [at
21 years]). Between-batch CVs for all these assays were
<3% in the normal range. Plasma insulin, proinsulin and 32–
33 split proinsulin were measured using a Delfia technique
(Victor 2; Wallac, Turku, Finland) at 8 years and a two-site
immunoenzymometric assay (Medgenix, Fleurus, Belgium) at
21 years; between-batch CVs for insulin measurements were
<6%. We recalculated HOMA-IR and HOMA-β at both
8 years and 21 years by the current accepted standard (online
Oxford HOMA calculator: available from www.dtu.ox.ac.uk,
accessed 15 July 2012) for consistency. There was an
excellent correlation (r=0.99, p<0.001) with HOMA-IR cal-
culated by the formula [32]. Insulin secretion was measured as
the insulinogenic index (increment in plasma insulin divided
by that in plasma glucose at 30 min) [33]. The Matsuda index
of insulin sensitivity was computed by the formula:
k=√ðfasting glucose 120 min glucose fasting insulin
120 min insulinÞ;
where k (constant)=10,000 [34].
Definitions
BMI was used to define overweight (≥25 and <30 kg/m2) and
obesity (≥30 kg/m2) [35]. Glycaemic classification was done
according to ADA (75 g OGTT) criteria: impaired fasting
glucose (IFG) as fasting plasma glucose 5.6–6.9 mmol/l and
120 min plasma glucose <7.8 mmol/l; impaired glucose toler-
ance (IGT) as fasting plasma glucose <5.6 mmol/l and
120 min plasma glucose 7.8–11.0 mmol/l; and diabetes
mellitus as fasting plasma glucose ≥7.0 mmol/l or 120 min
plasma glucose ≥11.1 mmol/l [11]. We defined prediabetes as
IFG and/or IGT. We defined hypercholesterolaemia
(≥5.1 mmol/l) according to National Cholesterol Education
Program criteria [36], and hypertriglyceridaemia
(≥1.7 mmol/l), low HDL-cholesterol (<1.03 mmol/l for male
participants and <1.29 mmol/l for female participants) and
hypertension (≥130/85 mmHg) by International Diabetes
Federation criteria [12].
Statistical methods
Variables with skewed distributions (insulin and triacylglycer-
ol concentrations, HOMA-IR, Matsuda index, HOMA-β,
insulinogenic index and IMT) were log-transformed to
achieve normality for analysis. The primary analysis was to
study associations of childhood glucose and insulin measure-
ments with CVD risk factors at 21 years of age. We tested for
linear and non-linear associations using regression. We per-
formed model checks by carrying out residual analysis and
confirmed the normality of residuals [37]. Both the exposure
and outcome variables were standardised to age- and sex-
specific z scores. The regression coefficients (β) therefore rep-
resent the SD change in outcome per SD change in exposure.
Glucose, insulin, BMI and skinfold thickness at 8 years were
strongly interrelated and could therefore confound associa-
tions with 21 year CVD risk factors. Therefore, we also used
residuals in these associations to test their independent rela-
tionships. For example, the residual of 8 year fasting glucose,
regressed upon 8 year fasting insulin, BMI and skinfold thick-
ness, was tested in addition to fasting glucose and so on. We
adjusted for multiple testing using the standard Bonferroni
correction (0.05 divided by number of outcomes [17]=
0.003) and used this value for statistical significance. We also
calculated the sensitivity, specificity, predictive values and
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receiver operating characteristic (ROC) AUC to assess the
relevance for clinical practice of high HOMA-IR in childhood
predicting CVD risk in young adulthood.
We performed sensitivity analyses between participants
and non-participants using regression imputation. We devel-
oped an imputation model using the variables significantly
associated with each other at 8 years in a multiple regression
model. We applied this regression imputation for participants
to calculate 21 year data and compared the imputed values
with available values. We imputed 21 year BMI using 8 year
age, BMI, total cholesterol, triacylglycerol, fasting insulin and
HOMA-IR as predictors. As there were no significant differ-
ences between observed and imputed values for participants
(indicating ‘missing at random’), we used this imputation
model to calculate 21 year data for the non-participants. We
then compared the observed values of the participants with the
imputed values of the non-participants.
Analysis was carried out using SPSS software (version
16.0; SPSS, Chicago, IL, USA).
Results
General characteristics
The characteristics of the 357 participants (191 boys) at 8 and
21 years of age are shown in Table 1. Glucose and insulin
concentrations and HOMA-IR at 8 years were no differ-
ent in these participants compared with those in the 120
who did not participate in the 21 year follow-up. Non-
participants had higher 8 year BMI (14.0 vs 13.6 kg/m2,
p=0.05) and greater skinfold thickness ( p<0.05, all)
compared with participants. Participants’ 21 year BMI
showed no differences with imputed values for non-
participants (21.6 vs 21.9 kg/m2; p>0.05).
At 21 years, 66 participants (18.5%) were overweight (21%
of boys and 15% of girls) and nine (2.5%) were obese (four
boys and five girls). Fifteen (4.2%) were hypertensive, 21
(5.8%) had high cholesterol, 27 (7.5%) had high triacylglyc-
erols, and 248 (69%) had low HDL-cholesterol. Three were
Table 1 Characteristics of the participants at 8 and 21 years of age
Characteristic 8 years 21 years
Male Female Male Female
N 191 166 191 166
Age, years 8.4 (0.1) 8.4 (0.1) 21.4 (0.4) 21.4 (0.4)
Height, cm 124.7 (10.6) 124.3 (6.1) 172.0 (6.6) 156.9 (6.4)***
Weight, kg 21.6 (3.6) 21.1 (3.9) 65.3 (13.1) 52.3 (10.6)***
BMI, kg/m2 13.7 (1.5) 13.5 (1.7) 22.0 (4.0) 21.2 (4.1)
WHR 0.82 (0.04) 0.82 (0.05) 0.86 (0.05) 0.79 (0.05)***
Fasting glucose, mmol/l 4.6 (0.6) 4.5 (0.6) 5.1 (0.6) 5.0 (0.4)*
30 min glucose, mmol/l 7.2 (1.4) 7.5 (1.4) 8.3 (1.3) 7.7 (1.4)***
120 min glucose, mmol/l 5.1 (4.2, 5.6) 5.1 (4.3, 5.7) 5.5 (4.8, 6.5) 5.7 (4.8, 6.5)
Fasting insulina, pmol/l 23.0 (16.0, 35.0) 26.0 (19.0, 35.0) 41.4 (26.1, 64.2) 48.0 (31.8, 68.4)
30 min insulina, pmol/l 173.5 (92.7, 268.2) 183.0 (119.7, 275.0) 495.6 (362.5, 705.6) 505.0 (327.4, 727.9)
120 min insulina, pmol/l 76.0 (40.0, 118.0) 98.0 (54.0, 167.0)** 297.0 (172.6, 488.2) 302.0 (199.5, 491.4)
HOMA-IRa 0.5 (0.3, 0.7) 0.6 (0.4, 0.7) 0.9 (0.6, 1.4) 1.0 (0.7, 1.5)
Matsuda indexa 17.0 (11.7, 26.4) 13.9 (9.3, 20.4)* 6.0 (3.8, 8.9) 5.2 (3.5, 8.0)
HOMA-βa 75.2 (56.4, 94.8) 76.1 (62.2, 98.3) 85.1 (60.2, 106.1) 94.5 (72.4, 122.5)**
Insulinogenic indexa 19.3 (11.0, 32.5) 20.6 (13.5, 31.4) 52.2 (37.8, 78.2) 58.1 (39.1, 83.1)
Systolic BP, mmHg 109.8 (14.1) 107.9 (19.5) 115.3 (10.1) 102.9 (9.1)***
Diastolic BP, mmHg 62.6 (9.7) 61.5 (13.8) 65.4 (8.4) 63.6 (7.9)*
Cholesterol, mmol/l 3.4 (0.6) 3.4 (0.6) 3.8 (0.7) 3.7 (0.7)
Triacylglycerolsa, mmol/l 0.7 (0.5, 0.9) 0.7 (0.6, 0.9) 0.8 (0.6, 1.2) 0.7 (0.6, 1.0)***
HDL-cholesterol, mmol/l 1.1 (0.2) 1.0 (0.3) 0.9 (0.1) 1.1 (0.2)***
IMTa, mm Not measured Not measured 0.37 (0.34, 0.42) 0.34 (0.32, 0.37)***
PWVa, cm/s Not measured Not measured 1,010.8 (947.3, 1,095.5) 885.0 (827.3, 958.6)***
Values are mean (SD) or amedian (25th–75th centiles) for skewed variables
p values were tested using ANOVA or the Mann–Whitney U test as appropriate
*p<0.05, **p<0.01, ***p<0.001
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already known to have diabetes (all on insulin treatment); we
diagnosed five new cases of diabetes and 61 of prediabetes (40
IFG and 21 IGT) at this follow-up. Acanthosis nigricans was
diagnosed in 42 (11.7%) at the age of 21 years. All but six had
a Framingham Risk Score of ≤3.
Sex differences
There were no differences in characteristics between boys and
girls at 8 years for anthropometric and biochemical variables.
All were considered prepubertal by the paediatrician on clin-
ical assessment. At 21 years, men were taller, heavier and had
higher glycaemia and CVD risk factors compared with wom-
en (Table 1). We present sex-adjusted results, as there was no
effect modification by sex.
Associations between childhood exposures and adulthood
outcomes
Cardiometabolic risk factors (Tables 2 and 3)
Fasting glucose at 8 years was directly related to 21 year
fasting and 120 min glucose and insulin concentrations,
HOMA-IR and cholesterol, and inversely to Matsuda index
and systolic BP; a 1 SD change was associated with a 0.10–
0.18 SD change. Eight year fasting glucose had no significant
associations with BMI and WHR at 21 years. The residual of
8 year glucose (independently of insulin, BMI and skinfold
thickness at 8 years) was significantly associated with fasting
glucose, HOMA-IR and IMT at 21 years.
Fasting insulin at 8 years was directly related to
21 year BMI, WHR, fasting glucose, fasting insulin,
120 min insulin, HOMA-IR, BP and triacylglycerols,
and inversely to Matsuda index and HDL-cholesterol;
a 1 SD change was associated with a 0.12–0.27 SD
change. The residual of 8 year insulin (independently
of glucose, BMI and skinfold thickness) showed similar
associations with 21 year insulin, systolic BP and lipid
variables. Insulin concentrations were directly related to
proinsulin and 32–33 split proinsulin concentrations
(r=∼0.4, p<0.001). Both proinsulin and split proinsulin
concentrations at 8 years were associated with a range
of CVD risk factors very similar to the associations of
insulin, but not independent of insulin concentrations
(data not shown).
Associations of HOMA-IR at 8 years were similar to those
of 8 year fasting insulin (Tables 2 and 3). Eight year HOMA-
IR was not related to either the presence or grade of acanthosis
nigricans at 21 years ( p=0.254). Individuals in the highest
quartile of HOMA-IR at 8 years had a higher risk of being
in the highest quartile of the following CVD risk factors at
21 years: BMI, WHR, 120 min insulin, HOMA-IR, systolic
and diastolic BP and triacylglycerols (RR 1.48–1.81; p<0.05,
all) (Table 4) compared with those in the lowest quartile.
Similarly, they were also more likely to be hyperglycaemic
(IFG+IGT+diabetes) at 21 years (RR 1.86; 95% CI 0.96,
3.60). Sensitivity and positive predictive values were low
(<40%), but specificity and negative predictive values were
in the range of 70–80%. ROC AUC values ranged from 50%
to 65%.
Associat ions of HOMA-β , Matsuda index and
insulinogenic index at 8 years with 21 years are shown in
Tables 2 and 3.
Fasting glucose, fasting insulin and HOMA-IR at 21 years
were significantly associated with a range of concurrent CVD
risk factors (electronic supplementary material [ESM]
Table 1). Fasting insulin and HOMA-IR at 21 years were
associated with acanthosis nigricans ( p=0.001, both), and
those with acanthosis nigricans had higher BMI, WHR and
other CVD risk factors (ESM Table 2). The 21 year associa-
tions were stronger than the corresponding associations of the
8 year measurements (Tables 2 and 3).
We compared 21 year CVD risk factors in those who were
in the highest quartile of HOMA-IR at both 8 and 21 years
with those who remained in the lowest quartile at both time
points. Those who remained in the highest quartile (n=31)
had a more adverse CVD risk profile compared with those
who remained in the lowest quartile (n=28) (ESM Table 3).
Four year measurements were available for 147 partici-
pants. Four year HOMA-IR was not significantly associated
with CVD risk factors at 21 years of age (data not shown),
although the direction of association and the effect size (β)
were similar to those at 8 years of age.
Vascular markers of atherosclerosis (Table 3)
We did not observe any significant plaques in any participant.
Fasting glucose at 8 years and its residual were significantly
associated with IMT at 21 years. There were no relationships
between 8 year glucose–insulin variables and PWV at
21 years. Higher glucose–insulin at 21 years and a higher
change in these variables between 8 and 21 years were asso-
ciated with higher PWV but not IMT. A 1 SD change in
glucose, insulin and HOMA-IR was associated with a 0.08–
0.13 SD change in PWV ( p<0.05, all).
Adjustments for dietary intake, physical activity
and socioeconomic status
In addition to age, sex, BMI and WHR, we adjusted our
models for diet (total calorie and macronutrient intakes), phys-
ical activity and socioeconomic status at 21 years. On
adjusting for physical activity, the relationships between 8 year
glucose, insulin and HOMA-IR and 21 year insulin and
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HOMA-IR became non-significant. Adjusting for dietary in-
take and socioeconomic class made no difference.
There was no evidence of non-linear associations in our
analyses.
Discussion
The Pune Children’s Study provides the first report of associ-
ations in India between glucose and insulin variables in child-
hood and a range of adult CVD risk factors including vascular
markers of atherosclerosis. Expectedly, at the young age of
21 years, there were only a few participants with diabetes,
hypertension and dyslipidaemia, and none had had a cardio-
vascular event. Sixty-nine (19.4%) had elevated glucose con-
centrations (eight diabetic, 61 prediabetic). Fasting glucose,
insulin and HOMA-IR at 8 years of age were related to
glycaemic variables and CVD risk factors at 21 years of age
independently of 8 year adiposity. Glucose–insulin at 21 years
and the change in glucose–insulin between 8 and 21 years had
a stronger association with 21 year CVD outcomes. Glucose at
8 years (but not insulin and HOMA-IR) was associated with
carotid IMT, while 21 year glucose–insulin and change be-
tween 8 and 21 years were associated with PWV.
A number of cross-sectional studies in children and adults,
as well as prospective studies in adults, have reported
associations of glucose, insulin and insulin resistance with
CVD risk factors [38–40]. The cross-sectional nature of these
studies, short-term follow-up and inability to account for pre-
existing pathology make it difficult to determine causality.
There are only a few prospective studies of CVD risk factors
from childhood to adulthood and few intervention trials in
childhood to test prevention across the life course. The best
known is the Bogalusa Heart Study, which studied children
into adulthood with serial measurements of CVD risk factors
to study associations and predictions. Among 1,606 children
who weremeasured in 1981–1982 and 1988–1991, those with
insulin levels in the highest quartile in both surveys had higher
BMI, triacylglycerols, LDL- and VLDL-cholesterol, systolic
and diastolic BP, and lower HDL-cholesterol at the second
survey compared with those with insulin in the lowest quartile
in both surveys. They also had higher incident obesity, hyper-
tension and dyslipidaemia [24]. In a 17 year follow-up of the
Bogalusa Heart Study, those with incident prediabetes and
diabetes were more likely to have been in the top decile for
glucose, insulin and HOMA-IR during childhood [23]. Our
findings for prediabetes and diabetes are similar and provide
stronger evidence to consider active intervention in childhood
to prevent later diabetes and CVD. It is of note that children in
the Bogalusa Heart Study cohort were enrolled across a wide
age range, spanning different pubertal stages, and the follow-
up rate was low (∼10–15% of the cohort were followed up at
Table 3 Associations of 8 year glucose and insulin variables and 21 year CVD risk factors
8 year variable 21 year variable
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Values are β regression coefficients (95% CI). All dependent and independent variables in a linear regression model are z-standardised
† p<0.003
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all time points). Moreover, the age range at follow-up was
broad (19–39 years) and ‘disease’ outcomes were ascertained
in only ∼5% of the original cohort. In another prospective
study, remarkable for its serial euglycaemic clamp measure-
ments in children at 13, 15 and 19 years of age, insulin resis-
tance and fasting insulin concentrations at age 13 were predic-
tive of triacylglycerol concentrations, BP and a metabolic syn-
drome score at 19 years, independently of BMI [41]. This
suggests that insulin resistance is an independent risk factor
for diabetes and CVD.
Broadly, the strength of associations of 8 year glucose,
insulin and HOMA-IR with 21 year CVD risk factors was
similar, although insulin was associated with a wider range
of CVD risk factors compared with glucose. Given the obser-
vational design and close interrelationships of these factors,
we are unable to comment on the relative importance of glu-
cose, insulin and insulin resistance for future outcomes.
Opinion is also divided as to whether glucose or insulin con-
centrations, or insulin resistance, are at the root of these asso-
ciations. Glucose might operate through its downstream met-
abolic pathways (‘glucotoxicity’) either in the pancreatic beta
cells or in the other tissues of the body. There is an interesting
possibility that requirement of insulin in certain tissues for the
entry of glucose might modulate these effects such that differ-
ent tissues are differently affected [42]. Reaven suggested that
insulin resistance is the root cause of type 2 diabetes and CVD
[15], based on cross-sectional observational studies in adults.
Insulin resistance implies a derangement in various intracellu-
lar pathways and these may affect metabolism, cellular growth
and proliferation in various tissues (endothelium, renal neph-
rons, sympathetic nervous system and liver), contributing to
increased CVD risk [43]. Recent research has highlighted a
possible role for epigenetic mechanisms in the pathogenesis of
vascular complications of diabetes [44]. In our study, we
found an interesting difference in the associations of markers
of atherosclerosis. IMT, a structural marker, was associated
only with 8 year glucose, while PWV, a functional marker,
was not associated with any 8 year measurements but with
21 year measurements and with change between 8 and
21 years in both glucose and insul in var iables .
Hyperglycaemia has been associated with increased PWV,
which may be partly due to the accumulation of AGEs in
elastin resulting in fracture of elastin and consequently stiffer
arteries [45]. Lack of association with IMT may be due to the
small variability at this young age of our participants. The
exact mechanisms involved need further investigation. In
adults there is evidence of a beneficial effect of lifestyle inter-
vention on the risk of diabetes [46, 47], although not always
on CVD. In our study, the confounding effect of physical
activity suggests a possible role for lifestyle interventions.
Our results suggest that the effect of childhood glucose–
insulin metabolism on adult CVD risk operates across the
‘normal’ range in a continuous manner. Those who tracked
as the most insulin resistant from childhood to adulthood had a
significantly worse CVD risk profile compared with those
who tracked as the most insulin sensitive, similar to the obser-
vations in the Bogalusa Heart Study. This is an important
observation to support a life course model for CVD risk and
Table 4 RR, sensitivity, specificity, predictive values and ROC AUC of being in the upper quartile of CVD risk factors at 21 years if in the upper
quartile of HOMA-IR at 8 years
Variable RR (95% CI) Sensitivity
(%)






BMI 1.81 (1.26, 2.60) 38.3 78.8 37.9 79.1 63.4
WHR 1.73 (1.20, 2.48) 37.2 78.4 36.7 78.7 62.3
Fasting glucose 1.35 (0.92, 1.99) 30.6 76.1 31.0 75.8 58.7
120 min glucose 1.17 (0.78, 1.76) 28.9 75.9 27.5 76.4 54.1
Fasting insulin 1.41 (0.96, 2.07) 32.9 76.6 32.1 77.2 60.5
120 min insulin 1.54 (1.06, 2.22) 34.4 77.6 34.8 77.3 60.0
HOMA-IR 1.65 (1.14, 2.38) 36.4 77.7 35.6 78.4 60.0
Matsuda index 1.46 (1.00, 2.13) 33.7 77.0 33.7 77.0 62.0
Insulinogenic index 0.95 (0.61, 1.45) 25.0 73.7 24.1 74.6 52.0
HOMA-β 0.54 (0.31, 0.92) 15.8 70.9 14.9 72.4 56.0
Systolic BP 1.48 (1.01, 2.15) 33.2 77.1 33.3 77.4 59.0
Diastolic BP 1.50 (1.03, 2.19) 34.1 77.2 33.3 77.8 56.7
Cholesterol 1.25 (0.84, 1.87) 30.1 75.8 28.7 77.0 53.2
Triacylglycerols 1.55 (1.07, 2.25) 34.8 77.5 34.8 77.8 61.1
HDL-cholesterol 1.28 (0.87, 1.88) 30.6 76.1 31.0 75.8 55.9
IMT 1.14 (0.73, 1.79) 29.8 73.8 27.4 76.1 55.0
PWV 1.19 (0.77, 1.84) 28.7 75.8 27.2 77.1 52.0
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it extends its generalisability from affluent populations to non-
obese, developing populations. The lack of association be-
tween 4 year and 21 year measurements may be because of
inadequate power. Although sensitivity, specificity and pre-
dictive values were generally low, a 1 SD increase in
HOMA-IR resulted in an increase in outcomes ranging from
0.1 mmol/l for glucose to 1.1 kg/m2 for BMI. Our study pro-
vides biologically important information and further work is
necessary to translate these findings into clinical practice for
identifying high risk children.
Our study has many strengths. Serial measurements
allowed us to examine the impact of childhood exposures on
adult outcomes. A narrow age range (CV <2%) and prepuber-
tal and postpubertal status at the two time points allowed us to
study CVD risk independently of these potential confounders.
In a meta-analysis, early puberty was associated with higher
adult BMI and risk of CVD [48]. Our results reinforce the life
course evolution of CVD risk before the onset of puberty. Our
loss to follow-up of ∼25% is one of the lowest for a long-term
longitudinal study and adds to its internal validity. Skinfold
thickness measurements allowed us to adjust for adiposity
(body fat) instead of only BMI. The procedures for measure-
ments at 8 and 21 years were comparable and were supervised
by the same observer (HGL). Sensitivity analyses using re-
gression imputation confirmed a lack of differential bias due
to follow-up loss.
There are a few limitations. The participants were born in
one hospital in Pune, which may limit generalisability.
However, the hospital is the second largest in Pune and offers
obstetric services to people from a wide range of socioeconom-
ic classes, thus improving representation. Rates of prediabetes
in our cohort were comparable to data from other urban Indian
studies [26–28]. Being an observational study, causality cannot
be established. Lack of multiple measurements of exposure
compromises assertion of temporality. However, as we were
examining the predictivity of 8 year glycaemic variables on
21 year outcomes, we believe there is a strong suggestion of
temporal relationships. Despite measurement of a number of
confounders, residual confounding cannot be ruled out. Our
interpretation of insulin resistance is predominantly based on
the HOMA model and not on euglycaemic clamp studies,
which would be impossible in our situation. However,
Matsuda index (a dynamic measure) [34] gave similar findings.
In summary, this is the first report of life course associa-
tions of CVD risk in young non-obese adults from a develop-
ing country. Higher glucose, insulin and insulin resistance in
childhood and a higher change in glucose–insulin between
childhood and young adulthood were associated with higher
CVD risk factors in early adulthood. Those who were persis-
tently insulin resistant had a higher CVD risk. Our previous
demonstration of an association between childhood insulin
resistance and low birthweight suggests that insulin resistance
may be on the pathway between fetal growth and CVD risk.
These findings reinforce the need for interventions in early life
to improve glucose–insulin metabolism to curtail the rapidly
escalating epidemics of diabetes and CVD. This may be
achieved by promoting healthy eating habits and physical ac-
tivity. Controlling excess weight gain in childhood may be
beneficial [49, 50]. Policy-makers should invest in the health
of children to improve the future health of the nation. This is
important because the prevention strategy is currently focused
on secondary and tertiary prevention. The Nobel laureate
economist James J. Heckman demonstrated that investment
early in life has substantially higher returns than later inter-
ventions [51].
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